Novartis India in the news

Milan Paleja has been appointed as the vice chairman and managing director of Novartis India, effective June 1, 2018, bringing extensive experience from various roles within Novartis.

Novartis India's stock rose nearly 10% on October 5th, driven by market recovery and the company's strategic shift to direct commercialization, aiming to double business in 4-5 years.

Novartis India's share price surged up to 10% on October 5th, driven by new private equity ownership and a retina medicine distribution deal, despite a high valuation and thin float.

Novartis India Limited officially changed its name to Evonile Pharma Limited as of October 1, 2026, following shareholder and government approval.

Novartis India Limited officially changed its name to Evonile Pharma Limited on October 1, 2026, following regulatory approvals.

Novartis India is experiencing a change in ownership, with Novartis AG divesting its stake, resulting in new investors, management changes, and a potential company name alteration, amidst fluctuating financial performance and market volatility.

Novartis India Ltd's rating was downgraded to Hold due to an expensive valuation and mixed technical signals, despite solid fundamentals and strong market outperformance.

Novartis India Limited changed its corporate name to Evonile Pharma Limited after receiving approval from the Ministry of Corporate Affairs.

Novartis India Limited changed its name to Evonile Pharma Limited on October 01, 2026.

Novartis India Limited shareholders approved a name change to Evonile Pharma Limited, passed an ESOP scheme, and ratified director appointments at its 78th AGM.

Novartis India's AGM approved an Employee Stock Option Scheme, regularized director appointments, approved a new MD & CEO, and sanctioned a company name change.

Novartis India Limited will participate in the Nuvama Emerging India CEO Forum on September 28, 2026, conducting in-person meetings without disclosing sensitive information.

Novartis India Limited has been added to the S&P Global BMI Index.

Novartis India, a pharmaceutical trading company, reported a yearly decline in revenue and profit for FY26, but showed strong quarterly growth in revenue, operating profit, and net profit for June 2026.

Novartis India acquired Pfizer's Minipress brands for $150 million, securing ownership of a well-known hypertension drug in the Indian market.

Novartis India Ltd's stock surged 7.55% to Rs 2116.6, reversing a recent downturn and significantly outperforming the broader market amidst a strong long-term uptrend.

Novartis India Limited's share price saw a sharp reversal following a strong upward trend, despite reporting a net profit of ₹32.21 crore in the June quarter.

Novartis India is revitalizing its market presence through strategic acquisitions and enhanced operational efficiencies, despite past revenue declines.

Novartis India's Country President and Managing Director, Amitabh Dube, has been appointed President of the Organisation of Pharmaceutical Producers of India (OPPI) for a two-year term, focusing on industry collaboration and innovation.

A major Novartis shareholder demands board changes and an overhaul of acquisition strategy after significant drug trial failures and stock value drops.